Coming Soon·Opens soon·Synced from source July 6, 2026
Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
Food and Drug Administration
Posted
Oct 23, 2025
Amount
$650,000 - $900,000
Closes
No deadline published by the funder
Last verified
Jul 6, 2026
At a glance
This funding opportunity is offered by Food and Drug Administration. Awards range from $650,000 to $900,000.
Classification and identifiers
- Solicitation number
- FOR-FD-25-001
- Assistance listing (CFDA)
- 93.103
Amount
$650,000 - $900,000
Who can apply
Special districtsState governmentsTribal organizationsNonprofits (non-501c3)Open to allTribal governments
About this opportunity
The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Related opportunities
- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)Food and Drug Administration
- Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Food and Drug AdministrationUp to $400K
- Studies Addressing Rare Neurodegenerative Diseases including ALSFood and Drug Administration
- Ancillary Studies to Ongoing Clinical Projects (RP1 Clinical Trial Not Allowed)National Institutes of Health
- INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)National Institutes of HealthCloses Jun 2028
- Research Grants in Clinical Informatics (R01 Clinical Trial Optional)National Institutes of HealthCloses Mar 2029Up to $250K
Finding similar opportunities...